fda compounding semaglutide crackdown 2025 news September 2, 2025: U.S. restrictions have stemmed a flood of compounded and tirzepatide – Partnership for Safe Medicines What Patients Need to Know

Evidence shows that stopping usually leads to rapid weight regain and loss of cardiometabolic benefits, suggesting these medications must be used long term to maintain health gains

Researchers following this literature should reference the published Phase 2 data as the current evidence base while monitoring Phase 3 publications for updated dosing information

GLP-1 (glucagon-like peptide-1) receptor agonists are a type of injectable medication originally developed to manage type 2 diabetes

Bangerter-Rhyner Foundation, and a top-up stipend from the PhD Program Health Sciences, University Hospital Basel, Switzerland (to COS)